Skip to main content

Table 1 Clinical characteristics of LUAD patients and LUSC patients

From: Comprehensive characterization of PD-L1 expression and immunotherapy-related genomic biomarkers in early- versus advanced-stage non-small cell lung cancer

Clinical characteristics

Overall

LUAD (N = 2476)

P

LUSC (N = 523)

P

(N = 3185)

I-III (N = 811)

IV (N = 1665)

I-III (N = 120)

IV (N = 403)

n (%)

n (%)

n (%)

n (%)

n (%)

Age (median, range)

61 (11–90)

58 (11–85)

61 (25–90)

< 0.001

64 (33–85)

65 (30–87)

0.359

Sex

  

Male

1892 (59.40)

393 (48.46)

902 (54.17)

0.0075

110 (91.67)

358 (88.83)

0.375

Female

1293 (40.60)

418 (51.54)

763 (45.83)

10 (8.33)

45 (11.17)

Smoking status

 

< 0.001

  

0.046

Ever

1068 (33.53)

154 (18.99)

408 (24.50)

 

105 (87.50)

324 (80.40)

 

Never

1427 (44.71)

463 (57.09)

857 (51.47)

7 (5.83)

49 (12.16)

Unknown

690 (21.66)

194 (23.92)

400 (24.02)

8 (6.67)

30 (7.44)

PD-L1 expression

 

< 0.001

  

0.058

High

457 (14.35)

61 (7.52)

266 (15.98)

 

22 (18.33)

84 (20.84)

 

Low

1131 (35.51)

270 (33.29)

582 (34.95)

63 (52.50)

163 (40.45)

 

Negative

1597 (50.14)

480 (59.19)

817 (49.07)

35 (29.17)

156 (38.17)

 

TMB

  

< 0.001

 

0.597

TMB-H

747 (23.45)

95 (11.71)

284 (17.06)

 

68 (56.67)

241 (59.80)

 

TMB-L

2438 (76.55)

716 (88.29)

1381 (82.94)

 

52 (43.33)

162 (40.20)

 

TMB (median, range)

4 (0-995)

2 (0-121.91)

3.84 (0-995)

0.012

10.56 (0-935.04)

10.56 (0-312)

0.123